190 related articles for article (PubMed ID: 36361809)
21. Microtubule Destabilizing Sulfonamides as an Alternative to Taxane-Based Chemotherapy.
González M; Ovejero-Sánchez M; Vicente-Blázquez A; Álvarez R; Herrero AB; Medarde M; González-Sarmiento R; Peláez R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33673002
[TBL] [Abstract][Full Text] [Related]
22. In vivo monitoring of the anti-angiogenic therapeutic effect of the pan-deacetylase inhibitor panobinostat by small animal PET in a mouse model of gastrointestinal cancers.
Maschauer S; Gahr S; Gandesiri M; Tripal P; Schneider-Stock R; Kuwert T; Ocker M; Prante O
Nucl Med Biol; 2016 Jan; 43(1):27-34. PubMed ID: 26702784
[TBL] [Abstract][Full Text] [Related]
23. Histone deacetylase inhibitor, panobinostat, exerts anti-proliferative effect with partial normalization from aberrant epigenetic states on granulosa cell tumor cell lines.
Hazama Y; Tsujioka T; Kitanaka A; Tohyama K; Shimoya K
PLoS One; 2022; 17(7):e0271245. PubMed ID: 35802681
[TBL] [Abstract][Full Text] [Related]
24. Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells.
Pettazzoni P; Pizzimenti S; Toaldo C; Sotomayor P; Tagliavacca L; Liu S; Wang D; Minelli R; Ellis L; Atadja P; Ciamporcero E; Dianzani MU; Barrera G; Pili R
Free Radic Biol Med; 2011 Jan; 50(2):313-22. PubMed ID: 21078383
[TBL] [Abstract][Full Text] [Related]
25. The pan-deacetylase inhibitor panobinostat suppresses the expression of oncogenic miRNAs in hepatocellular carcinoma cell lines.
Henrici A; Montalbano R; Neureiter D; Krause M; Stiewe T; Slater EP; Quint K; Ocker M; Di Fazio P
Mol Carcinog; 2015 Aug; 54(8):585-97. PubMed ID: 24375802
[TBL] [Abstract][Full Text] [Related]
26. Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer.
Wilson AJ; Gupta VG; Liu Q; Yull F; Crispens MA; Khabele D
Neoplasia; 2022 Feb; 24(2):63-75. PubMed ID: 34933276
[TBL] [Abstract][Full Text] [Related]
27. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
[TBL] [Abstract][Full Text] [Related]
28. Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro.
Chao H; Wang L; Hao J; Ni J; Chang L; Graham PH; Kearsley JH; Li Y
Cancer Lett; 2013 Feb; 329(1):17-26. PubMed ID: 22995071
[TBL] [Abstract][Full Text] [Related]
29. The HDAC inhibitor LBH589 induces ERK-dependent prometaphase arrest in prostate cancer via HDAC6 inactivation and down-regulation.
Chuang MJ; Wu ST; Tang SH; Lai XM; Lai HC; Hsu KH; Sun KH; Sun GH; Chang SY; Yu DS; Hsiao PW; Huang SM; Cha TL
PLoS One; 2013; 8(9):e73401. PubMed ID: 24023871
[TBL] [Abstract][Full Text] [Related]
30. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.
Rao R; Balusu R; Fiskus W; Mudunuru U; Venkannagari S; Chauhan L; Smith JE; Hembruff SL; Ha K; Atadja P; Bhalla KN
Mol Cancer Ther; 2012 Apr; 11(4):973-83. PubMed ID: 22367781
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat).
Kubo M; Kanaya N; Petrossian K; Ye J; Warden C; Liu Z; Nishimura R; Osako T; Okido M; Shimada K; Takahashi M; Chu P; Yuan YC; Chen S
Breast Cancer Res Treat; 2013 Jan; 137(1):93-107. PubMed ID: 23160924
[TBL] [Abstract][Full Text] [Related]
32. The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells.
Greve G; Schiffmann I; Pfeifer D; Pantic M; Schüler J; Lübbert M
BMC Cancer; 2015 Dec; 15():947. PubMed ID: 26675484
[TBL] [Abstract][Full Text] [Related]
33. The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways.
Bodo J; Zhao X; Sharma A; Hill BT; Portell CA; Lannutti BJ; Almasan A; Hsi ED
Br J Haematol; 2013 Oct; 163(1):72-80. PubMed ID: 23889282
[TBL] [Abstract][Full Text] [Related]
34. The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest.
Cheng YW; Liao LD; Yang Q; Chen Y; Nie PJ; Zhang XJ; Xie JJ; Shan BE; Zhao LM; Xu LY; Li EM
Cell Biochem Funct; 2018 Dec; 36(8):398-407. PubMed ID: 30484863
[TBL] [Abstract][Full Text] [Related]
35. Light-Controlled Histone Deacetylase (HDAC) Inhibitors: Towards Photopharmacological Chemotherapy.
Szymanski W; Ourailidou ME; Velema WA; Dekker FJ; Feringa BL
Chemistry; 2015 Nov; 21(46):16517-16524. PubMed ID: 26418117
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
[TBL] [Abstract][Full Text] [Related]
37. Panobinostat: The Small Molecule Metalloenzyme Inhibitor with Marvelous Anticancer Activity.
Ganai SA
Curr Top Med Chem; 2016; 16(4):427-34. PubMed ID: 26268342
[TBL] [Abstract][Full Text] [Related]
38. Histone Deacetylase Inhibitors Dose-Dependently Switch Neutrophil Death from NETosis to Apoptosis.
Hamam HJ; Palaniyar N
Biomolecules; 2019 May; 9(5):. PubMed ID: 31083537
[TBL] [Abstract][Full Text] [Related]
39. Panobinostat enhances NK cell cytotoxicity in soft tissue sarcoma.
Lu X; Liu M; Yang J; Que Y; Zhang X
Clin Exp Immunol; 2022 Aug; 209(2):127-139. PubMed ID: 35867577
[TBL] [Abstract][Full Text] [Related]
40. Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism.
Chen J; Fiskus W; Eaton K; Fernandez P; Wang Y; Rao R; Lee P; Joshi R; Yang Y; Kolhe R; Balusu R; Chappa P; Natarajan K; Jillella A; Atadja P; Bhalla KN
Blood; 2009 Apr; 113(17):4038-48. PubMed ID: 19074726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
